Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy

• Published in: PLoS neglected tropical diseases Vol. 14; no. 9; p. e0008583
• Main Authors: Lenz, Shannon M, Collins, Jaymes H, Ray, Nashone A, Hagge, Deanna A, Lahiri, Ramanuj, Adams, Linda B
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.09.2020; Public Library of Science (PLoS)
• Subjects: Animal models; Animals; Antibiotics; Asymptomatic Infections - therapy; Bacilli; Bacterial Load - drug effects; Biology and Life Sciences; Clarithromycin; Clarithromycin - therapeutic use; Clinical trials; Combination drug therapy; Deoxyribonucleic acid; Disease prophylaxis; Disease transmission; DNA; Drug Combinations; Drug dosages; Drug efficacy; Drugs; Engineering and Technology; Exposure; Funding; Growth; Health services; Infections; Inoculation; Inoculum; Laboratory animals; Leprostatic Agents - therapeutic use; Leprosy; Leprosy - drug therapy; Leprosy - transmission; Medical research; Medicine and Health Sciences; Methods; Mice; Mice, Nude; Minocycline; Minocycline - therapeutic use; Moxifloxacin; Moxifloxacin - therapeutic use; Mycobacterium leprae - drug effects; Mycobacterium leprae - growth & development; Nucleotide sequence; Ofloxacin; Patient outcomes; PCR; Post-Exposure Prophylaxis - methods; Prevention; Prophylaxis; Regression analysis; Research and Analysis Methods; Rifampin; Rifampin - analogs & derivatives; Rifampin - therapeutic use; Subclinical infection; Transmission; Tropical diseases; United States; Louisiana; Baton Rouge Louisiana; United States > US; Nepal

Subclinical infection with Mycobacterium leprae is one potential source of leprosy transmission, and post-exposure prophylaxis (PEP) regimens have been proposed to control this source. Because PEP trials require considerable investment, we applied a sensitive variation of the kinetic mouse footpad (...